WO2022265281A1 - 증숙생강 추출물 또는 이로부터 분리된 1-데하이드로-6-진저다이온을 유효성분으로 포함하는 퇴행성 관절염 예방, 개선, 또는 치료용 조성물 - Google Patents
증숙생강 추출물 또는 이로부터 분리된 1-데하이드로-6-진저다이온을 유효성분으로 포함하는 퇴행성 관절염 예방, 개선, 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2022265281A1 WO2022265281A1 PCT/KR2022/007917 KR2022007917W WO2022265281A1 WO 2022265281 A1 WO2022265281 A1 WO 2022265281A1 KR 2022007917 W KR2022007917 W KR 2022007917W WO 2022265281 A1 WO2022265281 A1 WO 2022265281A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dehydro
- ginger extract
- gingerdione
- degenerative arthritis
- steamed
- Prior art date
Links
- 235000020708 ginger extract Nutrition 0.000 title claims abstract description 128
- 229940002508 ginger extract Drugs 0.000 title claims abstract description 128
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 80
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- JUKHKHMSQCQHEN-VQHVLOKHSA-N [6]-Dehydrogingerdione Chemical compound CCCCCC(=O)CC(=O)\C=C\C1=CC=C(O)C(OC)=C1 JUKHKHMSQCQHEN-VQHVLOKHSA-N 0.000 title claims abstract description 51
- 239000004480 active ingredient Substances 0.000 title claims abstract description 23
- 210000000845 cartilage Anatomy 0.000 claims abstract description 39
- 230000014509 gene expression Effects 0.000 claims abstract description 38
- 238000004519 manufacturing process Methods 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- 230000008355 cartilage degradation Effects 0.000 claims abstract description 7
- 238000011084 recovery Methods 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 83
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 41
- 235000008397 ginger Nutrition 0.000 claims description 41
- 241000234314 Zingiber Species 0.000 claims description 37
- 235000013305 food Nutrition 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 10
- CZNLTCTYLMYLHL-UHFFFAOYSA-N [6]-Paradol Chemical compound CCCCCCCC(=O)CCC1=CC=C(O)C(OC)=C1 CZNLTCTYLMYLHL-UHFFFAOYSA-N 0.000 claims description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 9
- QOJHXMDTWFYFRL-PKNBQFBNSA-N (e)-1-(4-hydroxy-3-methoxyphenyl)dodec-1-ene-3,5-dione Chemical compound CCCCCCCC(=O)CC(=O)\C=C\C1=CC=C(O)C(OC)=C1 QOJHXMDTWFYFRL-PKNBQFBNSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000010025 steaming Methods 0.000 claims description 9
- 230000006872 improvement Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 claims description 7
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 108010074328 Interferon-gamma Proteins 0.000 claims description 6
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- BCIWKKMTBRYQJU-INIZCTEOSA-N (8)-Gingerol Chemical compound CCCCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 BCIWKKMTBRYQJU-INIZCTEOSA-N 0.000 claims description 5
- ZEASWHWETFMWCV-UHFFFAOYSA-N 7-O-(2-O-Acetyl-6-O-Methyl-beta-D-glucuronoside)-4',5,7-Trihydroxyflavone Natural products C=1C(O)=C(O)C2=C(O)C(=O)C=C(C3C(CC4=C(O)C=C(O)C=C4O3)OC(=O)C=3C=C(O)C(O)=C(O)C=3)C=C2C=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-UHFFFAOYSA-N 0.000 claims description 5
- VSDUZFOSJDMAFZ-UHFFFAOYSA-N 8-gingerol Natural products COC(=O)C(N)CC1=CC=CC=C1 VSDUZFOSJDMAFZ-UHFFFAOYSA-N 0.000 claims description 5
- AIULWNKTYPZYAN-UHFFFAOYSA-N 810gingerol Natural products CCCCCCCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 AIULWNKTYPZYAN-UHFFFAOYSA-N 0.000 claims description 5
- 102100037850 Interferon gamma Human genes 0.000 claims description 5
- TYQRTQZWHUXDLG-UHFFFAOYSA-N [8]-Paradol Chemical compound CCCCCCCCCC(=O)CCC1=CC=C(O)C(OC)=C1 TYQRTQZWHUXDLG-UHFFFAOYSA-N 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- AIULWNKTYPZYAN-SFHVURJKSA-N (10)-Gingerol Chemical compound CCCCCCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 AIULWNKTYPZYAN-SFHVURJKSA-N 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 102000004127 Cytokines Human genes 0.000 abstract description 17
- 108090000695 Cytokines Proteins 0.000 abstract description 17
- 230000002757 inflammatory effect Effects 0.000 abstract description 17
- 108010057466 NF-kappa B Proteins 0.000 abstract description 10
- 102000003945 NF-kappa B Human genes 0.000 abstract description 10
- 235000019441 ethanol Nutrition 0.000 description 31
- 235000002639 sodium chloride Nutrition 0.000 description 30
- 238000010171 animal model Methods 0.000 description 28
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 17
- -1 flakes Substances 0.000 description 16
- 239000000284 extract Substances 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 12
- 230000000692 anti-sense effect Effects 0.000 description 11
- 239000001768 carboxy methyl cellulose Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 229920000609 methyl cellulose Polymers 0.000 description 7
- 235000010981 methylcellulose Nutrition 0.000 description 7
- 239000001923 methylcellulose Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 6
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229960001031 glucose Drugs 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 244000299461 Theobroma cacao Species 0.000 description 4
- 244000273928 Zingiber officinale Species 0.000 description 4
- KMNVXQHNIWUUSE-UHFFFAOYSA-N [6]-Gingerdione Chemical compound CCCCCC(=O)CC(=O)CCC1=CC=C(O)C(OC)=C1 KMNVXQHNIWUUSE-UHFFFAOYSA-N 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000010603 microCT Methods 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 235000010413 sodium alginate Nutrition 0.000 description 4
- 239000000661 sodium alginate Substances 0.000 description 4
- 229940005550 sodium alginate Drugs 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 101100328886 Caenorhabditis elegans col-2 gene Proteins 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 102000011632 Caseins Human genes 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 3
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 238000010805 cDNA synthesis kit Methods 0.000 description 3
- 235000001046 cacaotero Nutrition 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 3
- 229960000590 celecoxib Drugs 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000001341 hydroxy propyl starch Substances 0.000 description 3
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 2
- 229940022682 acetone Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 235000015927 pasta Nutrition 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229960004025 sodium salicylate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- 229940045942 acetone sodium bisulfite Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- OIJMIQIDIZASII-UHFFFAOYSA-N benzene;benzoic acid Chemical compound C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 OIJMIQIDIZASII-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- LNUIUONEPHRXHM-UHFFFAOYSA-L disodium acetic acid ethane-1,2-diamine diacetate Chemical compound [Na+].[Na+].CC(O)=O.CC(O)=O.CC([O-])=O.CC([O-])=O.NCCN LNUIUONEPHRXHM-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000037231 joint health Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 229940072082 magnesium salicylate Drugs 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- IHYNKGRWCDKNEG-UHFFFAOYSA-N n-(4-bromophenyl)-2,6-dihydroxybenzamide Chemical compound OC1=CC=CC(O)=C1C(=O)NC1=CC=C(Br)C=C1 IHYNKGRWCDKNEG-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- YNJORDSKPXMABC-UHFFFAOYSA-N sodium;2-hydroxypropane-2-sulfonic acid Chemical compound [Na+].CC(C)(O)S(O)(=O)=O YNJORDSKPXMABC-UHFFFAOYSA-N 0.000 description 1
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940035023 sucrose monostearate Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001180 sulfating effect Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/10—General methods of cooking foods, e.g. by roasting or frying
- A23L5/13—General methods of cooking foods, e.g. by roasting or frying using water or steam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/10—Drying, dehydrating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Definitions
- the present invention relates to a composition for preventing, improving, or treating degenerative arthritis, comprising a steamed ginger extract or 1-dehydro-6-gingerdione isolated therefrom as an active ingredient.
- Degenerative arthritis is also called osteoarthritis, and the cartilage in the joint is continuously degraded and damaged by cytokines and cartilage degrading enzymes expressed in chondroocytes and synovial fluid through physical stimulation of the joint, resulting in damage to the joint surface. It refers to a condition in which motor function is lost and instability is induced. Osteoarthritis is the most common form of arthritis with a prevalence of about 60% in men and about 70% in women over the age of 65 years. Current treatment options for degenerative arthritis are limited and include symptomatic treatment with simple analgesics, non-steroidal anti-inflammatory drugs (NSAIDs) or intra-articular (IA) injectable glucocorticoid and hyaluronic acid (HA) formulations. Non-pharmacological measures range from physical exercise and weight loss to joint lavages and ultimately surgical joint replacement.
- NSAIDs non-steroidal anti-inflammatory drugs
- IA intra-articular injectable glucocorticoid and hyaluronic acid
- Nonsteroidal anti-inflammatory drugs such as ibuprofen, aspirin, and indomethacin, which are widely used for the treatment of arthritis, have the advantage of quick-acting, but cause damage to the gastrointestinal tract, which limits their long-term use.
- NSAIDs Nonsteroidal anti-inflammatory drugs
- ginger Zingiber officinale Roscoe
- Zingiber officinale Roscoe is a perennial tropical plant belonging to the Zingiberaceae family. There are about 47 genera and 1,400 species worldwide. is mainly cultivated in the high-temperature regions of tropical and temperate regions. In Korea, Yangha of the genus Ginger, Flower Ginger of the genus Ginger, and Yangha of the genus Flower ginger grow wild in the southern region.
- Ginger is registered as an edible food in Korea and has been edible for a long time in the US and Europe. -paradol, 1-dehydro-6-gingerdione, and 1-dehydro-8-gingerdione.
- rhizomes healthy
- roots, stems, and leaves are listed in the Food Code as edible, and single toxicity (rodents and non-rodents), three types of genotoxicity (reverse mutation, chromosomal abnormality, micronucleus) test) and 13-week repeated toxicity (rodent) test were performed to confirm safety.
- Dried rhizomes were used as medicines in oriental medicine such as Donguibogam, which was used to treat chills, fever, headache, vomiting, seawater, and phlegm caused by colds, and to treat symptoms such as stomach pain and diarrhea caused by food poisoning.
- ginger extract is known to be active in antioxidant, brain nerve protection, and improvement of gastrointestinal discomfort
- gingerol and shogaol the main components of ginger, are effective in metabolic syndrome such as diabetes, blood pressure and cholesterol lowering, in addition to antioxidant, anticancer, antibacterial, and neuroprotective effects. It is known that there is
- the present inventors attempted to develop a natural product-derived functional material for the prevention, improvement, or treatment of degenerative arthritis by analyzing various physiological activities using a steamed ginger extract obtained by steaming ginger.
- the inventors of the present invention are generally included in the process of making ginseng into red ginseng, which produces ingredients beneficial to the human body and has an absorption rate
- the steamed ginger extract was prepared by applying a steaming process that improves and enables long-term storage to ginger, and the effect of improving the degenerative arthritis was confirmed. Based on this, the present invention was completed.
- an object of the present invention is to provide a food composition for preventing or alleviating degenerative arthritis comprising a steamed ginger extract as an active ingredient.
- Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of degenerative arthritis comprising a steamed ginger extract as an active ingredient.
- Another object of the present invention is to provide a method for preparing a composition for preventing, improving, or treating degenerative arthritis using a steamed ginger extract.
- the present invention is a steamed ginger extract; 1-dehydro-6-gingerdione isolated therefrom; Or it provides a food composition for preventing or improving degenerative arthritis, including a food acceptable salt thereof as an active ingredient.
- the present invention steamed ginger extract; 1-dehydro-6-gingerdione isolated therefrom; Or it provides a pharmaceutical composition for preventing or treating degenerative arthritis, comprising a pharmaceutically acceptable salt thereof as an active ingredient.
- the food composition may be a health functional food composition, but is not limited thereto.
- the steamed ginger extract is water, C 1 to C 4 lower alcohol, n-hexane, ethyl acetate, acetone, acetonitrile, n-butyl acetate, 1,3-butylene glycol, methylene It may be extracted with one solvent selected from the group consisting of chloride and mixed solvents thereof, but is not limited thereto.
- the steamed ginger extract is 1-dehydro-6-gingerdione, 6-gingerol, 8-gingerol ), 10-gingerol, 6-shogaol, 6-paradol, 8-paradol, 1-dehydro-8-ginger It may include one or more selected from the group consisting of dione (1-dehydro-8-gingerdione), food acceptable salts thereof, and pharmaceutically acceptable salts thereof, but is not limited thereto.
- the 1-dehydro-6-gingerdione may be included in an amount of 0.001% to 10% by weight based on the dry weight of the steamed ginger extract, but is not limited thereto.
- the composition may reduce the expression of one or more selected from the group consisting of IL-1 ⁇ , TNF- ⁇ , IFN- ⁇ , and prostaglandin E 2 (PGE 2 ), but is not limited thereto.
- PGE 2 prostaglandin E 2
- the composition may have cartilage tissue recovery, cartilage production, or cartilage degradation inhibitory activity, but is not limited thereto.
- the composition may reduce the expression of I- ⁇ B or nuclear factor (NF)- ⁇ B protein, but is not limited thereto.
- NF nuclear factor
- the present invention steamed ginger extract; 1-dehydro-6-gingerdione isolated therefrom; Or it provides a method for treating or improving degenerative arthritis, comprising the step of administering a composition containing a pharmaceutically or food-wise acceptable salt thereof to a subject in need thereof.
- the present invention steamed ginger extract; 1-dehydro-6-gingerdione isolated therefrom; Or it provides a use for preventing, improving, or treating degenerative arthritis of a composition containing a pharmaceutically or food-wise acceptable salt thereof.
- the present invention steamed ginger extract; 1-dehydro-6-gingerdione isolated therefrom; Or it provides a use for the manufacture of a pharmaceutical or pharmaceutically acceptable salt thereof used for the prevention, improvement, or treatment of degenerative arthritis.
- the present invention provides a method for preparing a composition for preventing, improving, or treating degenerative arthritis, including the steamed ginger extract, comprising the following steps:
- the steamed ginger extract according to the present invention or 1-dehydro-6-gingerdione isolated therefrom exhibits effects of inhibiting inflammatory cytokine expression, cartilage tissue recovery, cartilage production, or cartilage degradation, and produces inflammatory cytokines and MMP It inhibits the expression of I- ⁇ B or NF- ⁇ B proteins involved in , and is expected to be usefully used in functional food compositions, pharmaceutical compositions, etc.
- 1 is a view showing changes in 1-dehydro-6-gingerdione in a ginger extract and a steamed ginger extract according to an embodiment of the present invention.
- Figure 2a is a view confirming the cytotoxicity (left figure) and NO production inhibitory effect (right figure) by the treatment of the steamed ginger extract according to one embodiment of the present invention.
- Figure 2b is a view confirming the cytotoxicity by treatment of the active ingredients of the steamed ginger extract according to one embodiment of the present invention.
- Figure 2c is a view confirming the change in NO production by treatment of the active ingredients of the steamed ginger extract according to one embodiment of the present invention.
- Figure 3a is a view confirming the change in mRNA expression of IL-1 ⁇ by treatment with a steamed ginger extract and 1-dehydro-6-ginger dione according to an embodiment of the present invention.
- Figure 3b is a view confirming changes in protein expression of IL-1 ⁇ by treatment with steamed ginger extract and 1-dehydro-6-ginger dione according to an embodiment of the present invention.
- Figure 4 schematically shows the process of inducing a degenerative arthritis animal model and administering a steamed ginger extract according to an embodiment of the present invention.
- 5a is a micro-CT image confirming changes in cartilage tissue structure by administration of a steamed ginger extract in an animal model with degenerative arthritis according to an embodiment of the present invention.
- Figure 5b is a diagram showing quantification of morphological indicators of cartilage tissue by administration of a steamed ginger extract in an animal model with degenerative arthritis according to an embodiment of the present invention.
- FIG. 6 is a view confirming changes in the expression of IL-1 ⁇ , TNF- ⁇ , and PGE 2 in the blood of an animal model for degenerative arthritis according to an embodiment of the present invention by administration of a steamed ginger extract.
- FIG. 7 is a diagram confirming changes in the expression of IL-1 ⁇ , IFN- ⁇ , and TNF- ⁇ in the cartilage of an animal model for degenerative arthritis according to an embodiment of the present invention by administration of a steamed ginger extract.
- FIG. 8 is a view confirming the expression changes of TIMP1, TIMP2, MMP-9, and COL-2 in cartilage of an animal model with degenerative arthritis according to an embodiment of the present invention by administration of a steamed ginger extract.
- FIG. 9 is a diagram confirming changes in the expression of I- ⁇ B and NF- ⁇ B proteins by administration of a steamed ginger extract in cartilage of an animal model with degenerative arthritis according to an embodiment of the present invention.
- ginger was steamed to prepare a steamed ginger extract (see Example 1).
- 6-shogaol, 6-gingerol, and 1-dehydro-6-gingerdione (1-dehydro-6 -gingerdione)
- 1-dehydro-6-gingerdione 1-dehydro-6 -gingerdione
- the steamed ginger extract reduced the expression of inflammatory cytokines in the blood or cartilage tissue of an animal model of degenerative arthritis induced by MIA (mono-iodoacetate), and inhibited cartilage tissue recovery, cartilage production, and cartilage degradation. activity, it was confirmed that the cartilage exhibits an effect of reducing the expression of I- ⁇ B and NF- ⁇ B proteins involved in the production of inflammatory cytokines and MMPs according to the progression of degenerative arthritis (see Experimental Example 2).
- the present invention steamed ginger extract; 1-dehydro-6-gingerdione isolated therefrom; Or it provides a food composition for preventing or improving degenerative arthritis, including a food acceptable salt thereof as an active ingredient.
- steaming generally refers to a process of steaming and cooking through heat treatment, and is a method of ripening by providing moist air at a constant temperature, and is widely used to manufacture ginseng into red ginseng. Steaming is one of the heat treatment methods for the purpose of long-term storage and distribution. It has been used as one of the methods.
- extract refers to an extract obtained by extracting the steamed ginger, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, or a mixture thereof, It includes the extract itself and extracts of all formulations that can be formed using the extract.
- the steamed ginger extract may be in the form of dry powder, but is not limited thereto.
- the method for extracting the steamed ginger is not particularly limited, and may be extracted according to a method commonly used in the art.
- Non-limiting examples of the extraction method include a hot water extraction method, an ultrasonic extraction method, a filtration method, a reflux extraction method, and the like, which may be performed alone or in combination of two or more methods.
- the type of extraction solvent used to extract the steamed ginger is not particularly limited, and according to a conventional method known in the art for extracting an extract from natural products, that is, under normal temperature and pressure conditions. It can be extracted using a common solvent.
- the steamed ginger extract is water, C 1 to C 4 lower alcohol, n -hexane, ethyl acetate, acetone, acetonitrile, n-butyl acetate, 1,3-butylene glycol, methylene chloride, And it may be extracted with one solvent selected from the group consisting of a mixed solvent thereof, and according to an embodiment of the present invention, extraction may be performed using ethanol as a solvent, but is not limited thereto.
- steamed ginger when steamed ginger is extracted using ethanol as a solvent, for example, 10% to 100% ethanol, 10% to 90% ethanol, 10% to 80% ethanol, 10% to 70% ethanol, 20% to 90% ethanol, 20% to 80% ethanol, 20% to 70% ethanol, 30% to 90% ethanol, 30% to 80% ethanol, 30% to 70% ethanol, 40% to 90% ethanol, 40% to 80% ethanol, 40% to 70% ethanol, 50% to 90% ethanol, 50% to 80% ethanol, 50% to 70% ethanol, 60% to 90% ethanol, 60% to 80% ethanol, 60% to 70% % ethanol, 65% to 75% ethanol, or 70% ethanol may be used, but is not limited thereto.
- the prepared extract may then be filtered or concentrated or dried to remove the solvent, and both filtration, concentration and drying may be performed.
- filtration may be performed using filter paper or a vacuum filter
- concentration may be performed using a vacuum concentrator
- drying may be performed by spray drying, freeze drying, etc., but is not limited thereto.
- osteoarthritis Also called osteoarthritis, it is the most common joint disease.
- the steamed ginger extract is 1-dehydro-6-gingerdione, 6-gingerol, 8-gingerol, 10- 10-gingerol, 6-shogaol, 6-paradol, 8-paradol, 1-dehydro-8-gingerdione (1 -dehydro-8-gingerdione), food acceptable salts thereof, and one or more selected from the group consisting of pharmaceutically acceptable salts thereof, but is not limited thereto.
- 1-dehydro-6-gingerdione is a compound of molecular formula C 17 H 22 O 4 , which is a kind of phenolic compound having a structure represented by Formula 1 below. , with a molecular weight of 290.4 (CAS No. 76060-35-0).
- the 1-dehydro-6-gingerdione may be isolated from steamed ginger, but is not limited thereto, and chemically synthesized or commercially available materials may be used by methods known in the art.
- the 1-dehydro-6-gingerdione is an indicator component of the steamed ginger extract, and its content may be 0.001% by weight or more relative to the dry weight of the steamed ginger extract, for example, 0.001% to 10% by weight.
- marker component refers to a component determined for the purpose of quality control among chemically identified components contained in raw materials, and is a standard substance for identifying herbal medicines.
- the term "acceptable salt in food science” includes salts derived from organic acids, inorganic acids, or bases acceptable in food science.
- "food” means a natural product or processed product containing one or more nutrients, preferably means a state that can be eaten directly through a certain degree of processing process, and usually means As, it means to include all health functional foods, beverages, food additives and beverage additives.
- the food composition may be a health functional food composition, but is not limited thereto.
- the "functional food” is the same term as food for special health use (FoSHU), medicine processed to efficiently display bioregulatory functions in addition to nutritional supply, It means a food with high medical effect, and can be manufactured into tablets, capsules, pills, granules, powders, liquids, flakes, pastes, syrups, gels, jellies, bars, or film formulations.
- “functionality” means obtaining useful effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological functions.
- the steamed ginger extract; 1-dehydro-6-ginger dione isolated therefrom; Or a food chemically acceptable salt thereof may be included as an active ingredient in a food composition for preventing or improving degenerative arthritis.
- active ingredient is a substance or substance group whose pharmacological action, directly or indirectly, is expected to be the efficacy and effect of the preparation, and the component is 1% by weight based on the dry weight of the total composition. More than may be included, for example, 10% to 100% by weight, 20% to 100% by weight, 30% to 100% by weight, 40% to 100% by weight, 50% to 100% by weight, 60% to 60% by weight 100 wt%, 70 wt% to 100 wt%, 80 wt% to 100 wt%, 90 wt% to 100 wt%, 10 wt% to 80 wt%, 20 wt% to 80 wt%, 30 wt% to 80 wt% %, 40% to 80% by weight, 50% to 80% by weight, 60% to 80% by weight, or 70% to 80% by weight may be included, but is not limited thereto.
- a food chemically acceptable salt thereof when used as a food additive, it may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to conventional methods.
- the mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment).
- a food chemically acceptable salt thereof may be added in an amount of 15% by weight or less, or 10% by weight or less based on the raw material.
- the amount in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount greater than the above range.
- Examples of foods to which the above substances can be added include meat, sausages, bread, chocolates, candies, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice creams, various soups, beverages, tea, drinks, There are alcoholic beverages and vitamin complexes, and includes all health functional foods in a conventional sense.
- the health beverage composition according to the present invention may contain various flavoring agents or natural carbohydrates as additional components, like conventional beverages.
- the aforementioned natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrins and cyclodextrins, and sugar alcohols such as xylitol, sorbitol and erythritol.
- natural sweeteners such as thaumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame may be used.
- the proportion of the natural carbohydrate is generally about 0.01-0.20 g, or about 0.04-0.10 g per 100 mL of the composition of the present invention.
- the composition of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, A carbonation agent used in carbonated beverages and the like may be contained.
- the composition of the present invention may contain fruit flesh for preparing natural fruit juice, fruit juice beverages and vegetable beverages. These components may be used independently or in combination. The ratio of these additives is not critical, but is generally selected in the range of 0.01-0.20 parts by weight per 100 parts by weight of the composition of the present invention.
- the present invention is a steamed ginger extract; 1-dehydro-6-gingerdione isolated therefrom; Or it provides a pharmaceutical composition for preventing or treating degenerative arthritis, comprising a pharmaceutically acceptable salt thereof as an active ingredient.
- salts include salts derived from inorganic acids, organic acids, or bases that are pharmaceutically acceptable.
- the present invention provides a steamed ginger extract; 1-dehydro-6-gingerdione isolated therefrom; Or it provides a method for treating or improving degenerative arthritis, comprising the step of administering a composition containing a pharmaceutically or food-wise acceptable salt thereof to a subject in need thereof.
- the present invention provides a steamed ginger extract; 1-dehydro-6-gingerdione isolated therefrom; Or it provides a use for preventing, improving, or treating degenerative arthritis of a composition containing a pharmaceutically or food-wise acceptable salt thereof.
- the present invention provides a steamed ginger extract; 1-dehydro-6-gingerdione isolated therefrom; Or it provides a use for the manufacture of a pharmaceutical or pharmaceutically acceptable salt thereof used for the prevention, improvement, or treatment of degenerative arthritis.
- prevention refers to any action that inhibits or delays the onset of degenerative arthritis
- treatment means that degenerative arthritis and metabolic abnormalities are improved or beneficially changed by administration of the pharmaceutical composition according to the present invention.
- Immulement means any activity that reduces the parameters related to degenerative arthritis, for example, the severity of symptoms, by administration of the composition according to the present invention.
- the pharmaceutical composition according to the present invention may further include suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
- the excipient may be, for example, one or more selected from the group consisting of a diluent, a binder, a disintegrant, a lubricant, an adsorbent, a moisturizer, a film-coating material, and a controlled release additive.
- compositions according to the present invention are powders, granules, sustained-release granules, enteric granules, solutions, eye drops, elsilic agents, emulsions, suspensions, spirits, troches, perfumes, and limonadese, respectively, according to conventional methods.
- tablets, sustained-release tablets, enteric tablets, sublingual tablets, hard capsules, soft capsules, sustained-release capsules, enteric capsules, pills, tinctures, soft extracts, dry extracts, fluid extracts, injections, capsules, perfusate It can be formulated and used in the form of an external agent such as a warning agent, lotion, pasta agent, spray, inhalant, patch, sterile injection solution, or aerosol, and the external agent is a cream, gel, patch, spray, ointment, warning agent , lotion, liniment, pasta, or cataplasma may have formulations such as the like.
- Carriers, excipients and diluents that may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
- Additives for the liquid formulation according to the present invention include water, dilute hydrochloric acid, dilute sulfuric acid, sodium citrate, sucrose monostearate, polyoxyethylene sorbitol fatty acid esters (tween esters), polyoxyethylene monoalkyl ethers, lanolin ethers, Lanolin esters, acetic acid, hydrochloric acid, aqueous ammonia, ammonium carbonate, potassium hydroxide, sodium hydroxide, prolamine, polyvinylpyrrolidone, ethyl cellulose, sodium carboxymethyl cellulose, and the like may be used.
- a solution of white sugar, other sugars, or a sweetener may be used, and aromatics, coloring agents, preservatives, stabilizers, suspending agents, emulsifiers, thickeners, etc. may be used as necessary.
- Purified water may be used in the emulsion according to the present invention, and emulsifiers, preservatives, stabilizers, fragrances, etc. may be used as needed.
- Suspension agents according to the present invention include acacia, tragacantha, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, sodium alginate, hydroxypropylmethylcellulose (HPMC), HPMC 1828, HPMC 2906, HPMC 2910, etc. Agents may be used, and surfactants, preservatives, stabilizers, colorants, and fragrances may be used as needed.
- Injections according to the present invention include distilled water for injection, 0.9% sodium chloride injection, IV injection, dextrose injection, dextrose + sodium chloride injection, PEG, lactated IV injection, ethanol, propylene glycol, non-volatile oil-sesame oil , solvents such as cottonseed oil, peanut oil, soybean oil, corn oil, ethyl oleate, isopropyl myristate, and benzene benzoate; solubilizing agents such as sodium benzoate, sodium salicylate, sodium acetate, urea, urethane, monoethylacetamide, butazolidine, propylene glycol, twins, nijuntinamide, hexamine, and dimethylacetamide; buffers such as weak acids and their salts (acetic acid and sodium acetate), weak bases and their salts (ammonia and ammonium acetate), organic compounds, proteins, albumin, peptone, and gums; tonicity agents such as sodium chlor
- the suppository according to the present invention includes cacao butter, lanolin, witapsol, polyethylene glycol, glycerogelatin, methylcellulose, carboxymethylcellulose, a mixture of stearic acid and oleic acid, subanal, cottonseed oil, peanut oil, palm oil, cacao butter + Cholesterol, Lecithin, Lannet Wax, Glycerol Monostearate, Tween or Span, Imhausen, Monolen (Propylene Glycol Monostearate), Glycerin, Adeps Solidus, Buytyrum Tego-G -G), Cebes Pharma 16, Hexalide Base 95, Cotomar, Hydroxycote SP, S-70-XXA, S-70-XX75 (S-70-XX95), Hyde Hydrokote 25, Hydrokote 711, Idropostal, Massa estrarium (A, AS, B, C, D, E, I, T), Massa-MF, Masupol, Masupol-15, Neos
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient, for example, starch, calcium carbonate, sucrose, etc. ) or by mixing lactose and gelatin.
- excipients for example, starch, calcium carbonate, sucrose, etc.
- lubricants such as magnesium stearate and talc are also used.
- Liquid preparations for oral administration include suspensions, solutions for oral administration, emulsions, syrups, etc.
- various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included.
- Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories.
- Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents.
- composition according to the present invention is administered in a pharmaceutically effective amount.
- pharmaceutically effective amount means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level is the type of patient's disease, severity, activity of the drug, It may be determined according to factors including sensitivity to the drug, administration time, route of administration and excretion rate, duration of treatment, drugs used concurrently, and other factors well known in the medical field.
- the pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple times. Considering all of the above factors, it is important to administer an amount that can obtain the maximum effect with the minimum amount without side effects, which can be easily determined by a person skilled in the art to which the present invention belongs.
- the pharmaceutical composition of the present invention can be administered to a subject by various routes. All modes of administration can be envisaged, eg oral administration, subcutaneous injection, intraperitoneal administration, intravenous injection, intramuscular injection, paraspinal space (intrathecal) injection, sublingual administration, buccal administration, intrarectal insertion, vaginal It can be administered by intraoral insertion, ocular administration, otic administration, nasal administration, inhalation, spraying through the mouth or nose, dermal administration, transdermal administration, and the like.
- the pharmaceutical composition of the present invention is determined according to the type of drug as an active ingredient together with various related factors such as the disease to be treated, the route of administration, the age, sex, weight and severity of the disease of the patient.
- steamed ginger extract; 1-dehydro-6-gingerdione isolated therefrom; food-acceptable salts thereof; or a pharmaceutically acceptable salt thereof is 200 to 600 mg, 250 to 600 mg, 300 to 600 mg, 350 to 600 mg, 400 to 600 mg, 450 to 600 mg, 200 to 550 mg, 200 to 500 mg per day , 250 to 550 mg, 250 to 500 mg, 300 to 550 mg, 300 to 500 mg, 350 to 550 mg, 350 to 500 mg, 400 to 550 mg, 400 to 500 mg, 450 to 550 mg, 450 to 500 mg , or at a dose of 480 mg, 6 to 18 weeks, 6 to 16 weeks, 6 to 14 weeks, 8 to 18 weeks, 8 to 16 weeks, 8 to 14 weeks, 10 to 18 weeks, 10 to 16 weeks, 10 to 10 weeks It may be administered to a subject for 14 weeks or 12 weeks, but is not limited thereto.
- “individual” means a subject in need of treatment of a disease, and more specifically, a human or non-human primate, mouse, rat, dog, cat, horse, and cow mammals such as
- administration means providing a given composition of the present invention to a subject by any suitable method.
- the present invention provides a method for preparing a composition for preventing, improving, or treating degenerative arthritis, including the steamed ginger extract, comprising the following steps:
- the steaming in step (a) is performed at 85 to 105 ° C, 90 to 105 ° C, 95 to 100 ° C, or 97 ° C for 1 to 3 hours, 1 to 2.5 hours, 1.5 to 3 hours, 1.5 to 1.5 hours. It may be performed for 2.5 hours or 2 hours, but is not limited thereto.
- the drying in step (b) may be carried out for 30 hours or more, for example, 30 to 50 hours at 40 to 60 °C, 45 to 60 °C, 45 to 55 °C, or 50 °C, 30 to 45 °C hour, 30 to 40 hours, or 30 to 35 hours, but is not limited thereto.
- the extraction in step (c) is 75 to 95 °C, 75 to 90 °C, 80 to 95 °C, 80 to 90 °C, or 85 °C 10 to 20 hours, 10 to 17 hours, 12 to It may be performed for 20 hours, 12 to 17 hours, or 15 hours, but is not limited thereto.
- the concentration under reduced pressure in step (d) may be performed at a temperature of 65 ° C or less, for example, 10 to 65 ° C, 20 to 65 ° C, 30 to 65 ° C, 40 to 65 ° C, 50 to 65 ° C °C, or 60 to 65 °C, and may be concentrated under reduced pressure to 20 brix or more, such as 20 to 100 brix, 20 to 80 brix, 20 to 60 brix, or 20 to 40 brix, but is not limited thereto. .
- the steamed ginger extract and carbohydrates are mixed in a ratio of 1:0.5 to 2, 1:0.5 to 1.5, 1:0.5 to 1, 1:1 to 2 , 1: 1 to 1.5, or may further include mixing at a dry weight ratio of 1: 1, and according to one embodiment of the present invention, the carbohydrate may be dextrin, but is not limited thereto.
- the step (e) is to heat the mixture of the steamed ginger extract and carbohydrates at 80 to 100 ° C, 85 to 100 ° C, 80 to 95 ° C, 85 to 95 ° C, or 90 ° C for 10 to 20 minutes, 10 to 100 ° C.
- a step of sterilizing for 17 minutes, 12 to 17 minutes, or 15 minutes may be further included, but is not limited thereto.
- the spray drying in step (e) has an inlet temperature of 180 to 200 ° C, 180 to 195 ° C, 185 to 200 ° C, 185 to 195 ° C, or 190 ° C, an outlet temperature It may be carried out in a dryer at 80 to 100 °C, 80 to 95 °C, 85 to 100 °C, 85 to 95 °C, or 90 °C, but is not limited thereto.
- Fresh ginger was purchased and its rhizome was used, and after washing with purified water for 5 to 7 minutes, the washed ginger was put into a steamer and steamed at 97 ° C. for 2 hours. Then, the steamed ginger was put in a dryer and dried at 50 ° C. for 30 hours or more to prepare steamed ginger.
- Example 1-1 70% alcohol (ethanol) was added 15 times to the raw material of steamed ginger prepared in Example 1-1, and extracted at 85 ° C. for 15 hours. Then, after filtering, the mixture was concentrated under reduced pressure to a concentration of 20 brix or higher at a low temperature of 65 °C or less, and filtered again. Then, the steamed ginger concentrate was mixed with dextrin, sterilized at 90 ° C for 15 minutes, and then spray-dried in a dryer with an inlet temperature of 190 ° C and an outlet temperature of 90 ° C to prepare a steamed ginger extract powder.
- ethanol 70% alcohol
- Samples were prepared by dissolving the steamed ginger extract and ginger extract in 80% methanol to prepare a 10,000 ppm solution, and then purifying with a 0.22 ⁇ m membrane filter (Woongki Science Co., Ltd., Seoul, Korea).
- HPLC used for analysis was Agilent Technologies 1260 series, and Cadenza CD-C18 (3 ⁇ m, 250 ⁇ 4.6 mm) was used as an analytical column.
- the measurement wavelength was 370 nm
- the sample injection amount was 10 ⁇ L
- the solvent elution rate was 0.4 mL/min
- water containing 0.1% formic acid (A) and acetonitrile were used as analysis solvents.
- (B) was used, and observation was performed for 60 minutes by changing the composition of the solvent as follows.
- 1-dehydro-6-gingerdione was set as the indicator component.
- 1-dehydro-6-gingerdione which is an indicator component in steamed ginger
- a calibration curve was prepared using a standard product, and based on the prepared calibration curve, 1-dehydro-6- It was confirmed that 1.18 mg/g of ginger dione was contained.
- the 1-dehydro-6-gingerdione content of the ginger extract was 0.54 mg/g.
- GE ginger extract
- GGE steamed ginger extract
- active ingredients of steamed ginger were used to confirm cell viability and NO production inhibitory effect.
- MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). Viable cells are measured for absorbance by converting MTT to formazan, and RAW 264.7 cells are inoculated in a 96-well plate at a concentration of 1 ⁇ 10 4 cells/well, then 37 °C, 5% CO It was cultured for 24 hours in an incubator under 2 conditions, and treated with ginger extract (GE) and steamed ginger extract (GGE) at concentrations of 25, 50, 100, and 200 ⁇ g/mL, and the active ingredients of steamed ginger were 1.3, 2.5, and 5 , 10, and 20 ⁇ g/mL concentrations, and incubated for 24 hours, then 10 ⁇ L of 5 mg/mL MTT solution was added and cultured for 2 hours. Then, the medium supernatant was removed, dissolved in 100 ⁇ L of DMSO, and absorbance was measured at 540 nm.
- RAW 264.7 cells were inoculated into a 96-well plate at a concentration of 1 ⁇ 10 4 cells/well, then cultured in an incubator at 37° C. and 5% CO 2 for 24 hours, and inflammation was induced.
- LPS lipopolysaccharide
- steamed ginger extract was treated at concentrations of 25, 50, 100, and 200 ⁇ g/mL
- active ingredients of steamed ginger were treated at 1.3, 2.5, and 5 , 10, 20 ⁇ g / mL concentration, incubated for 24 hours, transferred 50 ⁇ L of the supernatant to a new 96-well plate, added 50 ⁇ L of Griess reagent, and reacted at room temperature for 20 minutes
- Absorbance was measured at 450 nm.
- IL-1 ⁇ interleukin-1beta
- GGE steamed ginger extract
- 6-GD 1-dehydro-6-gingerdione
- RAW 264.7 cells were inoculated in a 6-well-plate at 1 ⁇ 10 4 cells/well, pretreated with LPS at a concentration of 1 ⁇ g/mL for 2 hours, and steamed ginger extract was prepared by concentration (50, 100, 200 ⁇ g/mL). mL) for 24 hours.
- Total RNA was extracted using TRIzol solution, RNA was quantified through Nanodrop, and the same amount of RNA was synthesized into cDNA using a cDNA synthesis kit (Takara, Japan), followed by qRT-PCR (quantitative real time-PCR). proceeded.
- interleukin-1 beta the protein was extracted using RIPA buffer, and the same amount of protein was electrophoresed with 12% SDS-PAGE and then transferred to a nitrocellulose membrane. transferred. After that, blocking was performed with 5% skim milk at room temperature for 1 hour, and then the primary antibody against IL-1 ⁇ (Invirogen, USA) was reacted at 4 ° C for one day, and enzymes and radioactive materials , or a secondary antibody (HPR-conjugated rabbit, Cell Signaling, USA) attached with a fluorescent substance or the like was reacted at room temperature for 1 hour. After 1 hour, proteins were detected with Lumi-Pico reagent.
- FIGS. 3a and 3b mRNA (FIG. 3a) and protein (FIG. 3b) expression of IL-1 ⁇ , an inflammatory cytokine, was increased by treatment with steamed ginger extract or 1-dehydro-6-gingerdione. confirmed to decrease.
- MIA mono-iodoacetate
- ginger extract 200 mg/kg
- steamed ginger extract 50, 100, 200 mg/kg
- celecoxib 10 mg/kg, celecoxib
- PC positive control group
- FIG. 4 The process of inducing the degenerative arthritis animal model and administering the steamed ginger extract as described above is shown schematically in FIG. 4 .
- ginger extract and steamed ginger extract were administered to animals with MIA-induced degenerative arthritis for 6 weeks, and blood was collected from the abdominal vein after fasting before autopsy, and serum was separated by centrifugation at 4 ° C. and 12,000 rpm for 15 minutes.
- serum was separated by centrifugation at 4 ° C. and 12,000 rpm for 15 minutes.
- the contents of IL-1 ⁇ , TNF- ⁇ , and PGE 2 were measured after reacting according to the manufacturer's experimental method with the items configured in the kit (R&D system, USA).
- MMPs Mestrix metalloproteinases
- TIMP tissue inhibitor of metalloproteinases
- COL COL involved in the generation of cartilage tissue Expression of -2 (collagen type II was confirmed.
- RNA was extracted from cartilage tissues of experimental animals using TRIzol reagent in the same manner as in Experimental Examples 2-4, and Nanodrop was used. After RNA was quantified through the quantification, the same amount of RNA was synthesized into cDNA using a cDNA synthesis kit (Takara, Japan), and then gene expression was confirmed using qRT-PCR.
- the steamed ginger extract according to the present invention exhibits cartilage degradation inhibitory and cartilage production effects in degenerative arthritis.
- I- ⁇ B and NF- ⁇ B proteins involved in the production of inflammatory cytokines and MMPs was confirmed in the cartilage of the MIA-induced osteoarthritis animal model according to the progression of degenerative arthritis.
- proteins were extracted from the cartilage tissue of experimental animals using RIPA buffer, and the same amount of protein was electrophoresed with 12% SDS-PAGE and then transferred to a nitrocellulose membrane. transferred to. After that, blocking was performed with 5% skim milk at room temperature for 1 hour, and then phospho-I ⁇ B (Santa Cruz, USA), I ⁇ B (Santa Cruz, USA), phospho-NF- ⁇ B (Cell Signaling, USA), and primary antibodies against NF- ⁇ B (Cell Signaling, USA) were reacted at 4 ° C for one day, and secondary antibodies (HPR-conjugated rabbit or mouse, Cell Signaling, USA) was reacted at room temperature for 1 hour. After 1 hour, proteins were detected and quantified with Lumi-Pico reagent.
- the steamed ginger extract according to the present invention or 1-dehydro-6-gingerdione isolated therefrom is expected to be usefully used in functional food compositions, pharmaceutical compositions, etc. for preventing, improving, or treating degenerative arthritis , has industrial applicability.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Gene | Primer sequences | 서열번호 |
IL-1β | 5'-GCAACTGTTCCTGAACTCAACT-3' (sense) | 1 |
5'-ATCTTTTGGGGTCCGTCAACT-3' (antisense) | 2 | |
β-actin | 5'-CGTGAAAAGATGACCAGAT-3' (sense) | 3 |
5'-ACCCTCATAGATGGCACA-3' (antisense) | 4 |
Gene | Primer sequences | 서열번호 |
IL-1β | 5'-CACCTCTCAAGCAGAGCACAGCACCTC-3′(sense) | 5 |
5'-GGGTTCCATGGTGAAGTCAAC-3′ (antisense) | 6 | |
TNF-α | 5'-TCGTCTACTACTCCTCAGAGCCC-3′(sense) | 7 |
5'-ACTTCAGCGTCTCGTGTGTT-3′(antisense) | 8 | |
IFN-γ | 5'-GCAAAGGACGGTAACACGAA-3′(sense) | 9 |
5'-ATGGCCTGGTTGTTGTCTTTCAAGA-3′(antisense) | 10 | |
β-actin | 5'-CGTGAAAAGATGACCCAGAT-3′(sense) | 11 |
5'-ACCCTCATAGATGGGCACA-3′(antisense) | 12 |
Gene | Primer sequences | 서열번호 |
MMP-9 | 5'-AGCCGGGAACGTATCTGGA-3′(sense) | 13 |
5'-TGGAAACTCACACGCCAGAAG-3′(antisense) | 14 | |
TIMP-1 | 5'-CATCTCTGGCCTCTGGCATC-3′(sense) | 15 |
5'-CATAACGCTGGTATAAGGTGGTCTC-3′(antisense) | 16 | |
TIMP-2 | 5'-CTGTGACCCAGTCCATCCAGAG-3′(sense) | 17 |
5'-GACACGCTTAGCATCACCCAGA-3′(antisense) | 18 | |
COL2 | 5'-CTGAGGGCTCCCAGAACATC-3′(sense) | 19 |
5'-TTCGTCCAGGTAGGCAATGC-3′(antisense) | 20 | |
β-actin | 5'-CGTGAAAAGATGACCCAGAT-3′(sense) | 11 |
5'-ACCCTCATAGATGGGCACA-3′(antisense) | 12 |
Claims (14)
- 증숙생강 추출물; 이로부터 분리된 1-데하이드로-6-진저다이온(1-dehydro-6-gingerdione); 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는, 퇴행성 관절염 예방 또는 개선용 식품 조성물.
- 제1항에 있어서,상기 식품 조성물은 건강기능성 식품 조성물인 것을 특징으로 하는, 퇴행성 관절염 예방 또는 개선용 식품 조성물.
- 제1항에 있어서,상기 증숙생강 추출물은 물, C1 내지 C4의 저급알코올, n-헥산, 에틸아세테이트, 아세톤, 아세토니트릴, n-부틸아세테이트, 1,3-부틸렌 글리콜, 메틸렌클로라이드, 및 이들의 혼합용매로 구성된 군으로부터 선택된 하나의 용매로 추출되는 것을 특징으로 하는, 퇴행성 관절염 예방 또는 개선용 식품 조성물.
- 제1항에 있어서,상기 증숙생강 추출물은 1-데하이드로-6-진저다이온(1-dehydro-6-gingerdione), 6-진저롤(6-gingerol), 8-진저롤(8-gingerol), 10-진저롤(10-gingerol), 6-쇼가올(6-shogaol), 6-파라돌(6-paradol), 8-파라돌(8-paradol), 1-데하이드로-8-진저다이온(1-dehydro-8-gingerdione), 및 이들의 식품학적으로 허용 가능한 염으로 이루어진 군으로부터 선택된 하나 이상을 포함하는 것을 특징으로 하는, 퇴행성 관절염 예방 또는 개선용 식품 조성물.
- 제4항에 있어서,상기 1-데하이드로-6-진저다이온은 증숙생강 추출물의 건조중량 대비 0.001 중량% 내지 10 중량%의 용량으로 포함되는 것을 특징으로 하는, 퇴행성 관절염 예방 또는 개선용 식품 조성물.
- 제1항에 있어서,상기 조성물은 인터루킨-1베타(IL-1β), 종양괴사인자 알파(TNF-α), 인터페론 감마(IFN-γ), 및 프로스타글란딘 E2(PGE2)로 이루어진 군으로부터 선택되는 하나 이상의 발현을 감소시키는 것을 특징으로 하는, 퇴행성 관절염 예방 또는 개선용 식품 조성물.
- 제1항에 있어서,상기 조성물은 연골 조직 회복, 연골 생성, 또는 연골 분해 억제 활성을 가지는 것을 특징으로 하는, 퇴행성 관절염 예방 또는 개선용 식품 조성물.
- 제1항에 있어서,상기 조성물은 I-κB 또는 핵 인자(NF)-κB 단백질의 발현을 감소시키는 것을 특징으로 하는, 퇴행성 관절염 예방 또는 개선용 식품 조성물.
- 증숙생강 추출물; 이로부터 분리된 1-데하이드로-6-진저다이온(1-dehydro-6-gingerdione); 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는, 퇴행성 관절염 예방 또는 치료용 약학적 조성물.
- 제9항에 있어서,상기 증숙생강 추출물은 1-데하이드로-6-진저다이온(1-dehydro-6-gingerdione), 6-진저롤(6-gingerol), 8-진저롤(8-gingerol), 10-진저롤(10-gingerol), 6-쇼가올(6-shogaol), 6-파라돌(6-paradol), 8-파라돌(8-paradol), 1-데하이드로-8-진저다이온(1-dehydro-8-gingerdione), 및 이들의 약학적으로 허용 가능한 염으로 이루어진 군으로부터 선택된 하나 이상을 포함하는 것을 특징으로 하는, 퇴행성 관절염 예방 또는 치료용 약학적 조성물.
- 하기 단계를 포함하는, 증숙생강 추출물을 포함하는 퇴행성 관절염 예방, 개선, 또는 치료용 조성물의 제조방법:(a) 생강을 세척하고 85 내지 105 ℃에서 1 내지 3시간 동안 증숙시키는 단계;(b) 증숙된 생강을 40 내지 60 ℃에서 30 내지 50시간 건조하는 단계;(c) 상기 건조시킨 증숙생강을 용매에 넣고 75 내지 95 ℃에서 10 내지 20시간 동안 추출하는 단계;(d) 상기 추출한 증숙생강을 여과하고 10 내지 65 ℃의 온도에서 감압농축하는 단계; 및(e) 상기 감압농축한 증숙생강 추출물을 여과하고 분무건조 하여 증숙생강 추출 분말을 제조하는 단계.
- 증숙생강 추출물; 이로부터 분리된 1-데하이드로-6-진저다이온(1-dehydro-6-gingerdione); 또는 이의 약학적 또는 식품학적으로 허용 가능한 염을 포함하는 조성물을 이를 필요로 하는 개체에 투여하는 단계를 포함하는, 퇴행성 관절염 치료 또는 개선 방법.
- 증숙생강 추출물; 이로부터 분리된 1-데하이드로-6-진저다이온(1-dehydro-6-gingerdione); 또는 이의 약학적 또는 식품학적으로 허용 가능한 염을 포함하는 조성물의 퇴행성 관절염 예방, 개선, 또는 치료 용도.
- 증숙생강 추출물; 이로부터 분리된 1-데하이드로-6-진저다이온(1-dehydro-6-gingerdione); 또는 이의 약학적 또는 식품학적으로 허용 가능한 염의 퇴행성 관절염 예방, 개선, 또는 치료에 이용되는 약제의 제조를 위한 용도.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280055481.9A CN117835837A (zh) | 2021-06-15 | 2022-06-03 | 用于预防、改善或治疗退行性关节炎的包含作为活性成分的蒸制姜提取物或从其分离的1-脱氢-6-姜二酮的组合物 |
EP22825207.8A EP4356756A1 (en) | 2021-06-15 | 2022-06-03 | Composition for preventing, improving, or treating degenerative arthritis comprising steamed ginger extract or 1-dehydro-6-gingerdione isolated therefrom as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0077699 | 2021-06-15 | ||
KR1020210077699A KR102647997B1 (ko) | 2021-06-15 | 2021-06-15 | 증숙생강 추출물 또는 이로부터 분리된 1-데하이드로-6-진저다이온을 유효성분으로 포함하는 퇴행성 관절염 예방, 개선, 또는 치료용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022265281A1 true WO2022265281A1 (ko) | 2022-12-22 |
Family
ID=84527177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/007917 WO2022265281A1 (ko) | 2021-06-15 | 2022-06-03 | 증숙생강 추출물 또는 이로부터 분리된 1-데하이드로-6-진저다이온을 유효성분으로 포함하는 퇴행성 관절염 예방, 개선, 또는 치료용 조성물 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4356756A1 (ko) |
KR (1) | KR102647997B1 (ko) |
CN (1) | CN117835837A (ko) |
WO (1) | WO2022265281A1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002047195A (ja) * | 2000-07-12 | 2002-02-12 | Pharmaceutical Industry Technology & Development Center | 生姜の有効成分を含む抽出物の製造方法、およびその抽出物を含む医薬組成物 |
KR20120020708A (ko) * | 2010-08-31 | 2012-03-08 | 박찬우 | 신규 처치법을 통한 [6]-쇼가올(shogaol)성분을 다량 함유한 가공된 생강을 제조하는 제조방법 |
KR20210077699A (ko) | 2018-10-08 | 2021-06-25 | 콴타 시스템 에스.피.에이. | 피부과 치료용 장치 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101895950B1 (ko) | 2015-12-18 | 2018-09-06 | (주)한국비엠아이 | 골관절염 치료를 위한 친수화된 설파살라진 및 히알루론산을 포함하는 조성물 및 이의제조방법 |
-
2021
- 2021-06-15 KR KR1020210077699A patent/KR102647997B1/ko active IP Right Grant
-
2022
- 2022-06-03 EP EP22825207.8A patent/EP4356756A1/en active Pending
- 2022-06-03 WO PCT/KR2022/007917 patent/WO2022265281A1/ko active Application Filing
- 2022-06-03 CN CN202280055481.9A patent/CN117835837A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002047195A (ja) * | 2000-07-12 | 2002-02-12 | Pharmaceutical Industry Technology & Development Center | 生姜の有効成分を含む抽出物の製造方法、およびその抽出物を含む医薬組成物 |
KR20120020708A (ko) * | 2010-08-31 | 2012-03-08 | 박찬우 | 신규 처치법을 통한 [6]-쇼가올(shogaol)성분을 다량 함유한 가공된 생강을 제조하는 제조방법 |
KR20210077699A (ko) | 2018-10-08 | 2021-06-25 | 콴타 시스템 에스.피.에이. | 피부과 치료용 장치 |
Non-Patent Citations (4)
Title |
---|
BARTELS E.M., FOLMER V.N., BLIDDAL H., ALTMAN R.D., JUHL C., TARP S., ZHANG W., CHRISTENSEN R.: "Efficacy and safety of ginger in osteoarthritis patients: a meta-analysis of randomized placebo-controlled trials", OSTEOARTHRITIS AND CARTILAGE, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 1, 1 January 2015 (2015-01-01), AMSTERDAM, NL, pages 13 - 21, XP093014842, ISSN: 1063-4584, DOI: 10.1016/j.joca.2014.09.024 * |
GRATAL P, LAMUEDRA A, MEDIERO A, HERRERO-BEAUMONT G, LARGO R, BONE: "THE GINGER DERIVATE 6-SHOGAOL AS A TREATMENT IN OSTEOARTHRITIS. MODULATION OF CHONDROCYTE HYPERTROPHY AND MATRIX CALCIFICATION", OSTEOARTHRITIS AND CARTILAGE, vol. 26, 1 April 2018 (2018-04-01), pages S73 - S74, XP093014840, DOI: 10.1016/j.joca.2018.02.156 * |
NAM YOUN HEE, HONG BIN NA, RODRIGUEZ ISABEL, PARK MIN SEON, JEONG SEO YULE, LEE YEONG-GEUN, SHIM JI HEON, YASMIN TAMANNA, KIM NA W: "Steamed Ginger May Enhance Insulin Secretion through KATP Channel Closure in Pancreatic β-Cells Potentially by Increasing 1-Dehydro-6-Gingerdione Content", NUTRIENTS, vol. 12, no. 2, pages 324, XP093014844, DOI: 10.3390/nu12020324 * |
no. 76060-35-0 |
Also Published As
Publication number | Publication date |
---|---|
KR20220168243A (ko) | 2022-12-23 |
KR102647997B1 (ko) | 2024-03-18 |
CN117835837A (zh) | 2024-04-05 |
EP4356756A1 (en) | 2024-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012074183A1 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases comprising trachelospermi caulis extract and paeonia suffruticosa andrews extract, and method for preparing the same | |
WO2018194309A1 (ko) | 인디루빈 유도체를 유효성분으로 포함하는 약학 조성물 | |
WO2012134126A2 (en) | Use of compounds isolated from morus bark | |
WO2016032249A1 (ko) | 모새나무 추출물 또는 이의 분획물을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌신경 질환의 예방 또는 치료용 약학적 조성물 | |
WO2011149301A2 (en) | A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases | |
WO2020218720A1 (ko) | 익모초 추출물 또는 레오누린을 함유하는 근육 질환 예방 또는 치료용 또는 근 기능 개선용 조성물 | |
WO2013141581A1 (ko) | 댕댕이나무열매 추출물을 유효성분으로 함유하는 허혈성 뇌혈관 질환의 예방 또는 개선용 약학적 조성물 또는 건강식품 | |
WO2020256464A1 (ko) | 항염 활성을 갖는 아피오스 아메리카나 괴경 추출물의 분획물의 알코올성 위염 예방 또는 치료제로서의 용도 및 이의 제조방법 | |
WO2021080297A1 (ko) | 달맞이꽃 추출물을 유효성분으로 포함하는 비만 또는 비만으로부터 유도된 대사증후군의 예방 또는 치료용 조성물 | |
WO2011099812A2 (ko) | 감초 추출물을 포함하는 로타바이러스 감염의 예방 또는 치료용 조성물 | |
WO2022265281A1 (ko) | 증숙생강 추출물 또는 이로부터 분리된 1-데하이드로-6-진저다이온을 유효성분으로 포함하는 퇴행성 관절염 예방, 개선, 또는 치료용 조성물 | |
WO2012108634A2 (ko) | 천궁 및 현호색의 혼합 생약 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물 | |
WO2019209061A1 (ko) | 총백을 유효성분으로 포함하는 뼈 성장 촉진용 조성물 | |
WO2019177428A1 (ko) | 호흡기 질환의 예방 또는 치료용 생약 조성물 | |
WO2011019153A2 (ko) | 오미자, 황금 및 해동피의 혼합 생약재 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 | |
WO2021080298A1 (ko) | 엔테로코커스 패칼리스를 유효성분으로 함유하는 비만 또는 비만으로부터 유도된 대사증후군의 예방 또는 치료용 조성물 | |
WO2015105373A1 (ko) | 화살나무 추출물 또는 이의 분획물을 포함하는 천식의 예방 또는 치료용 조성물 | |
WO2010143825A2 (en) | Anti-arthritic agent using cyathula officinalis | |
WO2019245245A1 (ko) | 강황 추출물을 포함하는 간손상 예방 및 치료용 약학 조성물 | |
WO2023017958A1 (en) | Composition for preventing, treating, or alleviating arthritis, comprising elaeocarpus sylvestris extract or mixture of elaeocarpus sylvestris extract and sulfasalazine as an active ingredient | |
WO2012173392A2 (ko) | 인플루엔자 바이러스 감염의 예방 또는 치료용 커큐미노이드계 화합물/스테비오사이드 함유 복합체 | |
WO2018190638A1 (ko) | 쥐눈이콩 추출물을 포함하는 각막 질환의 예방 또는 치료용 조성물 | |
WO2014126269A1 (ko) | 남성 성기능 개선 및 불임 치료용 약학적 조성물 | |
WO2024117763A1 (ko) | 산사나무 뿌리 추출물을 유효성분으로 포함하는 지방간 또는 비만의 예방 또는 치료용 약학적 조성물 | |
WO2023182757A1 (ko) | 뇌졸중의 예방 및 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22825207 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023577563 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022825207 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280055481.9 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2022825207 Country of ref document: EP Effective date: 20240115 |